Earnings Insights · OSCR · Q3 FY2026

Oscar Health Q3 2026 Earnings: Underwriting Gains Drive Another Outlook Increase

By AlgovestIQ ResearchPublished

Share

Read Oscar Health’s results announcement (Form 8-K, filed Nov 5, 2026)

Key earnings findings

Oscar Health (OSCR) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Oscar Health reported Q3 FY2026 revenue of $5.14B against the $4.69B analyst estimate, a 9.5% beat, and EPS of $0.49 against the -$0.14 analyst estimate.
  2. However, third-quarter revenue included a $250M favorable risk-adjustment update, and the company still expects a seasonal step-up in medical costs and administrative spending in the fourth quarter.
  3. OSCR closed at $33.18 on Nov 5, 2026, down 5.7% from $35.19 on Nov 4, 2026, the last close before the results were released.

Sources: Oscar Health results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Oscar Health beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$5.14B
$4.69B
+9.5%
EPS
$0.49
-$0.14
—
  • EPS has beaten the estimate in 3 of the most recent reported quarters.
  • Revenue surprise across the last 8 reported quarters has ranged from -15.3% to 9.6%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Oscar Health reported third-quarter revenue of $5.1B and GAAP diluted EPS of $0.49, reversing a $0.53 per-share loss a year earlier. Revenue rose about 72%, while a 450-basis-point improvement in medical loss ratio and a 350-basis-point reduction in the SG&A ratio pushed the company to $178.0M of operating income.

The main takeaway was not simply rapid top-line growth. Oscar’s 2026 underwriting economics have improved substantially, prompting its third increase to full-year operating-income guidance. However, third-quarter revenue included a $250M favorable risk-adjustment update, and the company still expects a seasonal step-up in medical costs and administrative spending in the fourth quarter.

Earnings Snapshot

MetricReportedChange
Total revenue$5.1BUp from $3.0B
Premium revenue$5.0BUp from $2.9B
Medical loss ratio84.0%Improved from 88.5%
SG&A expense ratio14.0%Improved from 17.5%
Earnings from operations$178.0MFrom a $129.3M loss
Net income attributable to Oscar$167.3MFrom a $137.5M loss
GAAP diluted EPS$0.49From a $0.53 loss
Adjusted EBITDA$206.9MFrom a $101.5M loss
Effectuated membership2.69MUp from 2.11M

The Bigger Story

Oscar’s third-quarter result reinforces that its improved 2026 profitability is being driven by both pricing and operating leverage rather than membership growth alone. Membership increased 27% year over year to 2.69 million, but the more consequential changes were a lower medical loss ratio, lower administrative-cost ratio, and a favorable revision to risk-adjustment estimates.

The company raised full-year operating-income guidance to $850M to $950M, its third increase this year. At the midpoint, that is $200M above the prior outlook and $550M above its original 2026 target, according to management.

Still, the quarter benefited from updated risk-adjustment data that added $250M to revenue. Management said the revision reflected Oscar’s improved risk profile relative to the market and modestly favorable market morbidity. Risk adjustment is a core feature of the ACA insurance market rather than a one-time accounting item, but the size of the quarterly revision means investors should distinguish the underlying underwriting trend from the unusually favorable timing of this update.

Revenue and Operating Performance

Total revenue increased to $5.1B from $3.0B in the prior-year period. Higher membership and rate increases drove the bulk of the growth. Premium revenue rose to $5.0B from $2.9B, while investment income increased to $91.0M from $53.2M.

The $250M favorable risk-adjustment update was a material contributor. Oscar reported that risk adjustment represented 11.8% of premiums in the third quarter, compared with 17.2% for the first nine months. Management reduced its expected full-year risk adjustment as a percentage of premiums to 17% to 18%, from a prior expectation of 20%.

Membership declined sequentially during the quarter due to disenrollments resulting from CMS eligibility reviews. Management said those changes were in line with expectations and anticipates a small number of additional disenrollments in the fourth quarter. Oscar now expects to end 2026 with roughly 2.5 million members.

For 2027, management expects the overall ACA marketplace to remain broadly stable relative to year-end 2026, while Oscar seeks market-share gains. Its footprint entering open enrollment is 24% larger, spanning 713 counties and 21 states following expansion into South Carolina. Management also cited approximately 850,000 members potentially becoming available through competitor exits.

The company is pursuing growth through new products and distribution tools as well. RetireEase has launched in selected markets, while hundreds of Oscar plans now offer dental and vision benefits. Its CHOICE offering, including the Hy-Vee Health with Oscar product, is expanding beyond Iowa into Nebraska, Missouri, and Kansas. These initiatives may broaden distribution and product reach, but they are not yet reported as material revenue contributors.

Profitability and Margins

Oscar’s medical loss ratio fell to 84.0% from 88.5% a year earlier. Management attributed the 450-basis-point improvement primarily to disciplined pricing. The company also recorded $42M of favorable prior-period development, compared with $84M in the prior-year quarter, suggesting the year-over-year MLR improvement was not driven by a larger reserve release.

Management said year-to-date utilization was moderately favorable to its expectations. Inpatient, professional, and pharmacy utilization were favorable, while outpatient utilization was elevated. The company characterized part of the outpatient increase as a shift from inpatient settings, helped by affordability and care-management initiatives. That mix shift can be economically favorable if it lowers the cost of care without increasing overall utilization.

SG&A expenses rose in dollar terms to $721.9M from $521.6M as the business expanded, but the expense ratio fell to a record-low 14.0% from 17.5%. Management cited lower risk adjustment as a share of premium, fixed-cost leverage, disciplined spending, and an increasing contribution from technology and AI initiatives.

The combination of better underwriting and lower relative overhead moved Oscar from a $129.3M operating loss in the prior-year quarter to $178.0M of operating income. Operating margin was 3.5%, compared with a negative margin a year ago. Net income was $167.3M, and adjusted EBITDA was $206.9M.

The fourth quarter is expected to be less favorable on a seasonal basis. Management expects an increase in the MLR as members reach deductibles and maximum out-of-pocket thresholds. It also expects the SG&A ratio to rise sequentially because of open-enrollment activity, fourth-quarter risk-adjustment chart collection, and investments for 2027 growth.

Demand, Customers and Pricing

Oscar is entering the 2027 enrollment season with a weighted average rate increase of approximately 14%. Management said the largest component is medical-cost trend in the high-single-digit range, followed by expected market-morbidity pressure from program-integrity efforts. The company also built some margin expansion into pricing.

Management believes its pricing remains competitive on a market-by-market basis, aided by provider-network relationships, broker distribution, and product design. It stressed that it does not need to be the lowest-priced plan in every market, citing member retention, service, and product quality as relevant competitive factors.

The outlook for ACA enrollment remains sensitive to policy and enrollment mechanics. Management expects enhanced eligibility and verification checks to create some friction early in open enrollment and to remove some members from the market. However, it expects new entrants to offset much of that attrition, leaving total marketplace enrollment broadly flat in 2027.

Oscar’s Lucie technology platform is expected by management to sell about 800,000 new policies in 2027. Those policies can include plans from other ACA carriers and supplemental carriers, so the figure should not be treated as expected Oscar insurance membership or premium revenue.

What is Oscar Health’s guidance for full-year 2026?

Oscar raised its full-year 2026 outlook:

MetricUpdated Full-Year 2026 OutlookPrior Outlook
Total revenue$19.0B to $19.3B$18.7B to $19.0B
Medical loss ratio80.5% to 81.5%81.0% to 82.0%
SG&A expense ratio15.1% to 15.6%15.6% to 16.1%
Earnings from operations$850M to $950M$600M to $800M

Management also expects adjusted EBITDA to be roughly $110M higher than earnings from operations for the full year.

For 2027, Oscar did not provide formal financial guidance. Management said it expects stable overall ACA marketplace membership, market-share gains for Oscar, further medical-cost improvement, and continued administrative efficiency. It plans to provide formal 2027 guidance with fourth-quarter results.

Management continues to target at least $4 in earnings per share by 2029. That is a long-term management target rather than a forecast for the coming year.

Balance Sheet, Cash Flow and Capital

Oscar ended September with $4.5B of cash and cash equivalents, $3.0B of short-term investments, and $1.4B of long-term investments. Total cash and investments were therefore approximately $8.9B, compared with about $5.5B at year-end 2025.

The increase reflects both improved profitability and insurance-related working-capital movements. Cash flow from operations was $3.5B through the first nine months, versus $423.0M a year earlier. However, operating cash flow also benefited from a $1.9B increase in payables to CMS and a $468.7M increase in benefits payable. These balances are inherent to Oscar’s role in the ACA risk-adjustment system and claims cycle, meaning cash generation should not be viewed solely as a measure of recurring free cash flow.

Long-term debt was $432.4M at September 30, essentially unchanged from year-end. Management said its insurance subsidiaries held approximately $2.3B of capital and surplus, including $1.4B of excess capital. The parent company held roughly $360M of cash and investments.

What Investors Should Watch

1. Fourth-Quarter MLR Seasonality

Oscar expects a meaningful sequential increase in its medical loss ratio during the fourth quarter. The degree of that increase will test whether favorable 2026 utilization and pricing trends are durable or partly offset by year-end member cost sharing and claims development.

2. Risk-Adjustment Development

The $250M third-quarter revenue benefit was a major driver of results and guidance. Investors should monitor whether future risk-adjustment data continues to support Oscar’s accruals, particularly as the company retains a cautious reserve posture.

3. 2027 Enrollment and Market Share

Management expects the ACA market to remain flat, leaving Oscar’s growth dependent on execution in new counties, South Carolina, new product categories, and competitor exits. The company’s ability to convert its expanded footprint into membership without sacrificing pricing discipline will be central.

4. Pricing Versus Medical Trend

Oscar’s approximately 14% average rate increase includes high-single-digit medical trend, expected morbidity pressure, and modest margin expansion. Claims experience in 2027 will show whether those pricing assumptions adequately cover utilization and changes in the risk pool.

5. Administrative Leverage

The 14.0% SG&A ratio was a record low, but management expects a fourth-quarter increase due to open-enrollment costs and growth investments. Sustained progress after those seasonal costs would support the case that Oscar’s scale and technology investments are producing structural operating leverage.

AlgovestIQ Takeaway

Oscar’s third quarter showed a substantial improvement in the economics of its ACA insurance business. Membership growth, higher pricing, lower medical costs relative to premium, and fixed-cost leverage drove the company from a sizable operating loss a year ago to a $178.0M operating profit.

The underwriting improvement appears meaningful. MLR declined despite less favorable prior-period development than in the year-earlier quarter, and management described utilization as generally favorable. SG&A leverage also stands out: administrative expenses grew far more slowly than revenue, taking the expense ratio to 14.0%.

The key qualification is revenue quality. The quarter included a $250M favorable risk-adjustment benefit, which meaningfully aided reported revenue and the higher full-year outlook. The risk-adjustment program is fundamental to ACA economics, but investors will need to assess future reserve development and claims costs rather than assume the third-quarter benefit recurs at the same scale.

The investment case is increasingly centered on whether Oscar can translate its stronger 2026 profitability into sustainable 2027 margin expansion while gaining share in a stable overall marketplace. Evidence of disciplined pricing, controlled fourth-quarter medical costs, durable administrative leverage, and successful enrollment in new markets would strengthen that case. A sharper-than-expected deterioration in market morbidity, policy-driven enrollment disruption, or a reversal in risk-adjustment favorability would weaken it.

How did OSCR stock react?

OSCR closed at $33.18 on Nov 5, 2026, down 5.7% from $35.19 on Nov 4, 2026, the last close before the results were released.

SessionCloseChange
Nov 4, 2026 (before release)$35.19—
Nov 5, 2026$33.18-5.7%
Nov 6, 2026$30.65-12.9%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Oscar Health Q3 FY2026 earnings call transcript, as of Nov 5, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Oscar Health Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 5, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 5, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.